SCHEMBL8622286

SCHEMBL8622286

CCC1CCc2cccc(N=C3NCCN3)c2C1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 4/20 0.38
HTR7 P34969 3/20 0.38
DRD2 P14416 2/20 0.38
HTR1D P28221 2/20 0.38
DRD3 P35462 2/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2D6 P10635 1/20 0.38
TSHR P16473 1/20 0.38
HTR1B P28222 1/20 0.38
HTR2A P28223 1/20 0.38
HTR2C P28335 1/20 0.38
ADRA1A P35348 1/20 0.38
ADRA1B P35368 1/20 0.38
HTR2B P41595 1/20 0.38
HTR5A P47898 1/20 0.38
BLM P54132 1/20 0.37
ALDH1A1 P00352 1/20 0.37
LMNA P02545 1/20 0.37
PMP22 Q01453 1/20 0.37
CHRM3 P20309 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8620926 0.90 CYP19A1 (0.40) HTR1AHTR7DRD2DRD3CHRM3
SCHEMBL8624076 0.82 CHRM3 (0.38) HTR1AHTR7DRD2HTR1DDRD3
SCHEMBL8619777 0.75 DRD2 (0.36) HTR1AHTR7DRD2DRD3CHRM3
Tramazoline SCHEMBL8623881 0.72 BCL2L1 (0.47) TSHRALDH1A1
SCHEMBL24210469 0.71 DRD2 (0.48) HTR1AHTR7DRD2DRD3CHRM3
SCHEMBL24210488 0.71 CYP2D6 (0.45) HTR1AHTR7DRD2HTR1DDRD3
SCHEMBL8625063 0.71 MTNR1A (0.30)
SCHEMBL8622487 0.71 SIGMAR1 (0.32) HTR1A
SCHEMBL599314 0.66 CYP19A1 (0.54) HTR1AADRA1AADRA1B
SCHEMBL8627077 0.66 HTR2C (0.35) HTR1ACYP2D6HTR2CADRA1ABLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5708015-A SENSITIVE ALPHA 2 ADRENERGIC RECEPTORS ALLERGAN (US) 1998-01-13 US disclosed
US-5580892-A ANTIDIARRHETIC, ANTISPASTIC, ANTIEPILEPTIC AGENTS; DIURETICS ALLERGAN 1996-12-03 US disclosed
EP-0724439-A1 USE OF 2-(2-ALKYLPHENYLAMINO)-OXAZOLINES, -THIAZOLINES AND -IMIDAZOLINES AS ALPHA 2 ADRENERGIC AGENTS Allergan (US) 1996-08-07 EP disclosed
WO-1995011021-A1 USE OF 2-(2-ALKYLPHENYLAMINO)-OXAZOLINES, -THIAZOLINES AND -IMIDAZOLINES AS ALPHA 2 ADRENERGIC AGENTS ALLERGAN (US) 1995-04-27 WO disclosed
US-5252595-A Method for reducing or maintaining intraocular pressure in the mammalian eye by administering pharmaceutical compositions containing 2-(2-alkylphenylamino)-oxazolines, 2-(2-alkylphenylamino)-thiazolines and 2-(2-alkylphenylamino)-imidazolines ALLERGAN, INC. (US) 1993-10-12 US disclosed